Proton pump inhibitor first strategy versus 'step-up' strategy for the treatment of reflux esophagitis: A cost-effectiveness analysis

Habu, Yasuki; Oyasu, Kazuya; Wakamatsu, Takahiro; Sumitomo, Yasuhiko; Ko, Kibon; Kiyota, Keisuke; Inokuchi, Hideto; Kawai, Keiichi

doi:10.1016/s0016-5085(00)82132-0

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cost‐effectiveness of a step‐down vs. a step‐up approach for empirical treatment has been analysed in several health economic papers. Our search revealed 10 papers and five abstracts addressing this question and, of these, seven papers and one abstract met our inclusion criteria 22, 28, 29, 30, 31, 41, 51, 53 . Most of these analyses showed that a step‐down approach resulted in superior symptom control as well as lower costs than a step‐up approach.…”

Section: Patients With Symptoms Who Have Not Undergone Endoscopy: Empmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review: patient‐centred endpoints in economic evaluations of gastro‐oesophageal reflux disease

Vakil¹,

Rydén‐Bergsten

Bergenheim

2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYAim: To perform a systematic review of the economic literature on gastro-oesophageal reflux disease to evaluate (a) the use of patient-centred effectiveness endpoints, or (b) the use of patient-centred economic end-points, and the influence of these end-points on the outcome of the model. Methods: Three electronic databases (EMBASE, BIOSIS and Medline) were used, together with a manual search of meeting abstracts for relevant articles. The quality of the studies was determined by the Drummond criteria. Results: Our initial search identified 179 articles and a manual search revealed 78 abstracts and articles. A total of 47 studies (36 fully published articles and 11 abstracts) met the seven Drummond criteria for inclusion in our evaluation. Conclusions: This systematic review demonstrates that many of the published economic evaluations available today take the perspective of the third-party payer and focus on pharmaceutical costs relevant to the thirdparty payer. Our study also demonstrates that there are a number of costs of illness determinations, such that pharmaceutical costs account for only a small proportion of the total costs of managing gastro-oesophageal reflux disease. Future economic analyses should consider an evaluation of the patient's desire for complete symptom relief by including cost-utility assessments or willingness to pay data.

show abstract

Section: Patients With Symptoms Who Have Not Undergone Endoscopy: Empmentioning

confidence: 99%

“…EOCEAPPIs (omeprazole (branded), lansoprazole, pantoprazole) & H 2 RAs (branded & generic) & cisaprideLong‐term therapy/ treatment strategiesGreen et al 30 UI GERDCEAOmeprazole & generic ranitidineStep therapyHabu et al 31 EOCEAPPIs & H 2 RAStep therapyHarris et al 32 …”

Section: Appendixmentioning

confidence: 99%

Systematic review: patient‐centred endpoints in economic evaluations of gastro‐oesophageal reflux disease

Vakil¹,

Rydén‐Bergsten

Bergenheim

2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…3 health economics. Treating gastro-oesophageal reflux disease (GORD) in Japanese data supported the use of PPIs as first-line any of its manifestations, from erosive oesophagitis to therapy for reflux oesophagitis in preference to a step-up nonerosive reflux, is rapidly becoming an exercise in strategy.…”

mentioning

confidence: 99%

News from Digestive Disease Week 2000

2000

Pharmacoecon. Outcomes News

View full text Add to dashboard Cite

Proton pump inhibitor first strategy versus 'step-up' strategy for the treatment of reflux esophagitis: A cost-effectiveness analysis

Cited by 2 publications

References 0 publications

Systematic review: patient‐centred endpoints in economic evaluations of gastro‐oesophageal reflux disease

Systematic review: patient‐centred endpoints in economic evaluations of gastro‐oesophageal reflux disease

News from Digestive Disease Week 2000

Contact Info

Product

Resources

About